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Schizophrenia patients show significant subcortical brain abnormalities. We examined these
abnormalities using automated image analysis software and provide effect size estimates for
prospective multi-scanner schizophrenia studies. Subcortical and intracranial volumes were
obtained using FreeSurfer 5.0.0 from high-resolution structural imaging scans from 186
schizophrenia patients (mean age±SD=38.9±11.6, 78% males) and 176 demographically similar
controls (mean age±SD=37.5±11.2, 72% males). Scans were acquired from seven 3-Tesla
scanners. Univariate mixed model regression analyses compared between-group volume
differences. Weighted mean effect sizes (and number of subjects needed for 80% power at
α=0.05) were computed based on the individual single site studies as well as on the overall multi-
site study. Schizophrenia patients have significantly smaller intracranial, amygdala, and
hippocampus volumes and larger lateral ventricle, putamen and pallidum volumes compared with
healthy volunteers. Weighted mean effect sizes based on single site studies were generally larger
than effect sizes computed based on analysis of the overall multi-site sample. Prospectively
collected structural imaging data can be combined across sites to increase statistical power for
meaningful group comparisons. Even when using similar scan protocols at each scanner, some
between-site variance remains. The multi-scanner effect sizes provided by this study should help
in the design of future multi-scanner schizophrenia imaging studies.
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1. Introduction
Schizophrenia patients show significant structural brain abnormalities when studied with
magnetic resonance imaging (MRI). In vivo study of these abnormalities may aid in our
understanding of etiology, pathogenesis, and treatment effects. In this study we examine
whether subcortical volume alterations can be observed in prospective multi-center imaging
studies despite additional between-scanner variance. We provide effect size estimates for
single center (based on meta-analysis of single site effects) versus multi-center (based on
mega-analysis correcting for site effects) structural imaging studies in schizophrenia.
Effect size estimates for structural brain alterations in schizophrenia are predominantly
based on single center studies (Haijma et al., 2013; Shepherd et al., 2012); but for a
simulation of multi-center study effect sizes, see Suckling et al. (Suckling et al., 2010). The
increase in multi-scanner imaging studies, as well as increased efforts towards data sharing,
emphasizes the need for effect-size estimates for multi-scanner data acquisitions. The ability
to detect statistically significant differences between conditions depends on the effect size,
sample size, α-level, and power of the test (Cohen, 1992). In power analyses, the researcher
sets the desired α-level and power of the test. The effect size is preferably gleaned from the
literature or otherwise estimated, and the sample size that will be required to observe a
statistically significant effect is estimated.
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The effect size for mean comparisons can be computed as the mean difference between two
conditions divided by the pooled standard deviation of the measurements (Cohen, 1992) and
thus depends on measurement variability. In single scanner studies, such variability depends
on subject variability, between-acquisition scanner variability, and measurement-method
reliability. In multi-scanner studies it also depends on between-scanner and other between-
site (e.g., sample demographics) variance. Subject variability depends on the relative
homogeneity or heterogeneity of the sample(s). Between-acquisition scanner variability
depends on the stability over time of the MRI scanner. Brain-measurement reliabilities are
estimated from multiple measurements on the same cases and include inter- and intra-
scanner reliability (Jovicich et al., 2009), rater reliability (van Erp et al., 2004), and
measurement-method reliability (Dewey et al., 2010; Tae et al., 2008; Wonderlick et al.,
2009).
Measurements should not only be reliable but also valid. A measure is considered valid
when the inferences made from it are appropriate, meaningful, and useful. The calculation of
inter-method reliability in which a new method is compared to a GOLD standard, or a
method that has been shown to produce valid measurements, provides one way to validate a
measurement method. The more similar the measurements are (the higher the intra-class
correlation), the more valid the measurements based on the new method. Nevertheless,
validation should also be established by confirming that meaningful variability can be
observed with the measurements.
Given between-scanner variability, the question remains as to how many additional data sets
need to be collected in multi-scanner versus single scanner studies to observe differences
between schizophrenia patients and controls? In this study, we compare subcortical volumes
between chronic schizophrenia patients and healthy volunteers, and we report the weighted
mean effect sizes as well as multi-center-based (n=7) effect sizes for subcortical volumes.
Based on the effect sizes reported in meta-analyses (Haijma et al., 2012; Shepherd et al.,
2012) (see Table 4), we hypothesized that we would find smaller amygdala, hippocampus,
and intracranial volume and larger lateral ventricle and pallidum volumes in patients with
schizophrenia compared with healthy volunteers.
2. Methods
2.1. Participants
The participants comprised 186 schizophrenia patients (mean age±SD=38.9±11.6, 145
males) and 176 healthy volunteers (mean age±SD=37.5±11.2, 126 males) with similar mean
age, sex, handedness, and race distributions from seven sites (Table 1; see Supplement 1,
Table 1S, for demographic data by site). Patient inclusion criteria were schizophrenia
diagnosis based on the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (First
et al., 2002b). All patients were clinically stable outpatients whose antipsychotic
medications and doses had not changed within the last 2 months. Current neuroleptic
medication data were available for 171 of the 186 patients (antipsychotics: 136 atypical, 20
typical, 10 both; mood stabilizers: 2, and anxiolytics: 3). Chlorpromazine-equivalent
dosages could be computed for 151 patients (Woods et al., 2005). Schizophrenia patients
and healthy volunteers with a history of major medical illness, drug dependence in the last 5
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years, current substance abuse disorder, MRI contraindications, or eyesight not correctable
to normal acuity with MRI-compatible lenses were excluded. Patients with significant
extrapyramidal symptoms and healthy volunteers with a current or past history of major
neurological or psychiatric illness (First et al., 2002a) or with a first degree relative with an
Axis-I psychotic disorder diagnosis were also excluded. Patient’s clinical assessments
included the Positive and Negative Syndrome Scale (Kay et al., 1989). All participants were
assessed for socioeconomic status (Hollingstead, 1975), handedness (Oldfield, 1971), basic
demographics, and premorbid IQ (Uttl, 2002). The sample includes 137 paranoid, 7
disorganized, 30 undifferentiated, and 12 residual patients. Before data collection,
experienced clinicians were jointly trained on the clinical assessment rating scales with
patient interviews. The raters’ assessments were compared with expert ratings. Additional
training was provided when raters deviated by more than 1 point for each item from the
expert ratings.
Written informed consent, including permission to share de-identified data between the
centers and with the wider research community, approved by the University of California
Irvine, Los Angeles, and San Francisco, Duke University, University of North Carolina,
New Mexico, Iowa, and Minnesota Institutional Review Boards, was obtained from all study
participants.
2.2. Image acquisition
High-resolution structural brain scans were acquired on six 3T Siemens Tim® Trio System
and one 3T General Electric (GE) Discovery MR750 scanner using standardized sequences.
Siemens MP-RAGE scan parameters were: TR/TE/TI=2300/2.94/1100 ms, flip angle=9°,
resolution=256×256×160. GE IR-SPGR scan parameters were: TR/TE/TI=5.95/1.99/450
ms, flip angle=12°, resolution=256×256×166. All scans covered the entire brain with field
of view (FOV)=220 mm2, voxel size=0.86×0.86×1.2mm, sagittal scan plane, GRAPPA/
ASSET acceleration factor=2, and number of excitations (NEX)=1. The 3T MRI scanners at
each site were calibrated to meet FBIRN Phantom quality assurance (Friedman and Glover,
2006a, 2006b; Greve et al., 2011), and scanner quality was monitored during the entire
study. Before the study began, a traveling engineer visited each site to review MRI study
protocol adherence based on FBIRN’s multi-center imaging study recommendations (Glover
et al., 2012).
2.3. Image processing
Left and right lateral ventricle, thalamus, caudate, putamen, pallidum, hippocampus, and
amygdala volumes as well as intracranial volumes (Table 2; see Supplement 1, Table 2S for
absolute volumes by site) were obtained using Freesurfer Version 5.0.0 (http://
surfer.nmr.mgh.harvard.edu; (Fischl, 2012; Fischl et al., 2002). All regions of interest with a
volume larger or smaller than 1.5 times the inter-quartile range (IQR) were identified and
visually inspected by overlaying them on the subject’s anatomical images. Based on these
inspections, data from one patient were removed due to poor image quality and 0–2
additional data points for each of the regions of interest were eliminated from the final
analyses.
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Group differences for each region were examined using univariate mixed model regression
analyses (Proc Mixed, SAS v9.2, SAS Institute Inc.) predicting subcortical volumes with
group, site, sex, age, group × site, group × hemisphere, site × hemisphere, and group × site ×
hemisphere interactions. Hemisphere and intracranial volume entered the model as repeated
measures and covariate variables, respectively. For the regions with a-priori-defined
directional hypotheses based on the literature (amygdala, hippocampus, intracranial, lateral
ventricle, and pallidum), the significance threshold was set at p<0.05 (one-tailed). We also
indicate which of the findings pass the more conservative Bonferroni multiple comparison-
corrected threshold of p<0.00625 (two-tailed). Based on evidence for the effects of
antipsychotic medication on basal ganglia volumes (Gur et al., 1998; Hulshoff Pol and
Kahn, 2008; Boonstra et al., 2011; Li et al., 2011), we examined the effect of current
antipsychotic medication type (typical/atypical) and dose (chlorpromazine-equivalent dose)
on basal ganglia volumes, using mixed model regression and correlation analysis,
respectively. Cohen’s d weighted mean effect sizes based on each of the seven single site
samples and also based on the full sample were computed. Sample size estimates were based




There were significant effects of group (schizophrenia patient, healthy volunteer) on
hippocampus, pallidum, putamen, lateral ventricle, amygdala and intracranial volumes (Figs.
1A–1F), with hippocampus, amygdala, and intracranial volumes smaller and pallidum,
putamen, and lateral ventricle volumes larger in schizophrenia patients compared with
controls (Table 3, Fig. 1; see Supplement 1, Table 3Sp for statistical results by site). The
effects for hippocampus and pallidum also passed the conservative Bonferroni two-tailed -
value threshold of p<0.00625.
3.2. Site and group by site interaction effects
There were significant effects of site on hippocampus, putamen, thalamus, and intracranial
volume, and a marginal effect of site (p=0.05) on caudate volume. Group × site interactions
were confined to the amygdala. Decomposition of the interaction effect showed that at one
site amygdala volume in patients was larger than in controls (t349=2.97, p=0.003), at two
sites amygdala volume was smaller in patients compared with controls (t349=−2.57, p=0.01;
t349=−2.0, p<0.05), and at four sites amygdala volumes did not differ between the groups
(t349=0.05, p=0.96; t349=−1.36, p=0.17; t349=0.19, p=0.85, t349=−0.07, p=0.94).
3.3. Other effects
There were significant hemisphere effects on all subcortical volumes (Table 3) with left
hippocampus, amygdala, caudate, and thalamus volumes smaller than right, and right
putamen, pallidum, and ventricular volumes smaller than left (Table 2). There were
significant hemisphere × site interactions on amygdala, pallidum, and thalamus volumes.
Decomposition of the hemisphere × site interactions showed that left amygdala, pallidum,
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and thalamus volumes were smaller than right for all the sites, but that the strength of the
differences varied by site. There were significant effects of sex on hippocampus, amygdala,
putamen, pallidum, and intracranial volumes, with women showing smaller volumes than
men. Age showed a significant negative association with subcortical and intracranial
volumes and a significant positive association with lateral ventricle volumes. Intracranial
volume was positively associated with all measured volumes (Table 3).
3.4. Effect-size estimates
The effect sizes based on the full multisite sample were on average 13% smaller than the
effect-size estimates based on the weighted mean effect sizes from each individual site
(Table 4). The sample sizes required for 80% power at α-level=0.05 for the five regions that
showed significant group differences were between 1.3 and 3.4 times larger for multi-
scanner compared with single scanner data acquisitions.
3.5. Antipsychotic medications
Current medication dose in chlorpromazine equivalents was negatively associated with left
caudate (r150=−0.16, p<0.05), and left and right putamen (r150=−0.20, p=0.01; r150=−0.19,
p=0.02)volumes. There were no effects of typical versus atypical antipsychotics on any of
the regions.
4. Discussion
The principal findings of this study are as follows: (1) that we confirm smaller hippocampus,
amygdala, and intracranial volumes and larger lateral ventricle, putamen, and pallidum
volumes in patients with schizophrenia compared with healthy volunteers based on a
prospective seven-site imaging study; (2) that significant site effects are present for
hippocampus, putamen, thalamus, and intracranial volumes; and (3) that effect sizes for
regional volume differences based on the multisite sample analysis were on average 13%
smaller than those based on the weighted single site sample means.
The findings of smaller hippocampus, amygdala, and intracranial volumes and larger lateral
ventricle, putamen, and pallidum volumes in patients with schizophrenia compared with
healthy volunteers are consistent with and validate those observed in single site studies
(Shepherd et al., 2012). While ventricle size showed the largest percentage between-group
difference in volume, consistent with the fact that this is among the most robust structural
brain abnormalities observed in patients with schizophrenia, surprisingly its effect size was
relatively small. The effect size for amygdala volume deficit in schizophrenia patients
compared with controls was also relatively small (see Table 4) (Shepherd et al., 2012). The
relatively small effect sizes for these regions are unlikely due to multi-scanner acquisition
given that for these regions (a) site effects are not significant and (b) the weighted single-
scanner and multi-site effect sizes are quite similar. The small effect size for ventricle
volume is likely due to large variability in this sample (see SD, Table 2). With regard to
amygdala volumes, FreeSurfer reliability estimates are high (Jovicich et al., 2009; Morey et
al., 2010), but validity may be questionable given reports of relatively low correlations with
volumes derived from manual amygdala tracings (amygdala: r=0.56; for comparison
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hippocampus: r=0.82) (Morey et al., 2009), though see Dewey et al. (Dewey et al., 2010).
Lower amygdala volumes are generally not observed in first episode schizophrenia, but
there is high-moderate quality evidence for lower amygdala volumes in chronic
schizophrenia (Shepherd et al., 2012). Given that our sample is older than in those reported
in the meta-analyses of Shepherd et al. (2012) and Haijama et al. (2012), demographic
differences other than age (e.g., medication treatment, diagnoses) may play a role. For
instance, significantly lower amygdala volumes are also observed in patients with mood
disorders (Hamilton et al., 2008; Sacher et al., 2012), and future work should investigate
whether lower amygdala volumes are more robust in patients with schizoaffective disorder
than schizophrenia. Schizoaffective disorder patients are often included in schizophrenia
studies but are excluded from this study.
It is not surprising that we did not find group differences for caudate and thalamus volumes
as the ranges of effect sizes for these structures in chronic schizophrenia patients include 0,
though caudate and thalamus volumes appear lower in antipsychotic-naïve patients and may
normalize after medication treatment (Haijma et al., 2012; Shepherd et al., 2012). In contrast
to our expectations, we found that current medication doses in chlorpromazine equivalents
were negatively associated with left caudate and bilateral putamen volumes. These findings
are in contrast to longitudinal studies that have reported that antipsychotic treatments
normalize caudate volume deficits observed in medication-naïve patients (Haijma et al.,
2012) and increase putamen and pallidum volumes (Boonstra et al., 2011; Gur et al., 1998;
Hulshoff Pol and Kahn, 2008; Li et al., 2011), though additional, systematic, long-term (> 1
year) longitudinal studies are likely required to more fully understand the effects of
antipsychotic treatment on brain morphology.
Right-left asymmetries for hippocampus, amygdala, caudate, and lateral ventricle, as well as
left-right asymmetries for putamen and pallidum volumes, have been reported in studies
using gold-standard manual tracing methods (Aas et al., 2012; Erdogan et al., 2004; Peterson
et al., 1993; Van Erp et al., 2002), and similar asymmetries observed in this study lend
credibility to the quality of FreeSurfer’s automated segmentations.
In the analyses on the full data set, we found significant effects of site on hippocampus
putamen, thalamus, and intracranial volumes. These site effects may be due to differences in
sample demographics between sites or differences between scanners. Upon further
investigation, the observed effect of site was mainly due to higher volumes produced by site
1 (GE scanner, sample with lowest mean age). When data from this center were excluded
from the analysis, all effects of site, except for those on the hippocampus, were rendered
non-significant. Closer investigation showed that the remaining site effect was due to lower
hippocampus volumes for site 3 compared with all the other sites and that patients in this
site had significantly older mean age than those of the other sites. While determination of
scanner effects requires a traveling subject study, in which the same subjects are scanned at
different sites, the main take-home message from our analysis is that careful consideration
of site effects may provide clues about factors that influence sample heterogeneity in
observed associations.
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To our knowledge, this is the first multi-site study of subcortical brain volumes in chronic
schizophrenia that provides estimates of the costs associated with multi-site versus single
site data collection/analysis by providing effect sizes for mega- vs. meta-analysis of multi-
center data. When analyzing data from seven scanners, we observed the need for on average
a 1.26 to 3.4 times increase in sample size to detect the same volume differences observed
when conducting single scanner studies. In contrast to an earlier report (Jovicich et al.,
2009), we found that multi-site acquisition of hippocampus volume data required a 1.26
times larger data sample to obtain similar statistical power to that of data acquisition at a
single scanner.
Strengths of the study are as follows: (1) the results are based on a largely fully automated
analysis with few exclusions of subjects based on quality-assurance procedures; (2) the
study includes a large cohort of chronic schizophrenia patients and controls such that
variance estimates and therefore effect size estimates are likely to be robust; (3) the study
includes data collected from seven scanners – albeit six Siemens 3T and one General
Electric 3T– providing ample opportunity for between-scanner variability; and (4) the study
was carefully planned and used the FBIRN phantom for scanner calibration, a traveling
engineer to review protocol compliance before study initiation, and standardized scan
sequences across scanners (Friedman and Glover, 2006a, 2006b; Greve et al., 2011; Glover
et al., 2012)
Some study weaknesses must be noted as follow: (1) the focus of FBIRN was not on
improving brain morphometric measures across scanners and included a standard high-
resolution T1-weighted scan for registration purposes in functional imaging studies. Hence,
higher effect sizes may be obtained for sequences optimized for morphometric studies
(Jovicich et al., 2009); (2) the study included only one GE and no Philips scanners; (3) the
study did not measure lifetime medication exposure or employ a longitudinal design to study
medication effects; and (4) demographics were balanced within site, but variance in
demographics (mean age, race distribution, and sex distribution) between sites was allowed.
Such variance can improve generalizability of findings, but it also contributes to sample
heterogeneity. Whether to allow for such variance should be taken into account when
planning multi-center studies.
In conclusion, we were able to confirm the observations of smaller hippocampus, amygdala,
and intracranial volumes and larger lateral ventricle, putamen, and pallidum volumes in
patients with schizophrenia compared with healthy volunteers in a carefully planned
prospective, multi-site imaging study. The effect sizes provided should help in the design of
future multi-scanner schizophrenia imaging studies. Although some extra data collection is
required in multi-scanner studies, benefits of multi-center data collection (Glover et al.,
2012) may in many cases outweigh the cost.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Regional volume differences between patients and controls across and within site. 1A-F:
Regional volume differences based on multi-site analyses; 1G-L: Regional volume
differences based on within-site analyses (due to lack of group by hemisphere interactions,
data are collapsed across hemisphere in the within-site figures).
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Table 1
Sample Demographics
Schizophrenia Patients (n=186) Healthy Volunteers (n=176) Statistic p- value
Mean Age (SD) 38.9 (11.6) 37.5 (11.2) t360=1.12 0.26
Subject Educationb (SD) 3.4(0.9) 2.3(0.9) t360=11.47 <0.0001
Parental Educationb (SD) 2.4(1.8) 2.1(1.5) t360=1.49 0.14
NAART 29.4(12.4) 39.7(11.4) t357= −8.22 <0.0001
Age at Onset 21.8 (7.6)





Gender (M/F) 145/41 126/50 χ21=0.83 0.36
Handednessa (bilateral/left/right) 4/12/170 2/7/167 FET 0.46
Race FET 0.10
 American Indian or Alaskan 4 3
Native
 Asian 22 16
 Black or African American 38 20
 Native Hawaiian or Pacific 2 2
Islander
 White 120 135
FET=Fisher’s Exact Test
a
based on Edinburgh Handedness Inventory (Oldfield, 1971)
b
based on the Hollingstead Socioeconomic Status Scale (Hollingstead, 1975)
NAART = North American Adult Reading Test (Uttl, 2002)
PANSS = Positive and Negative Syndrome Scale (Kay et al., 1989)
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Table 2
Absolute Volumes
Region Schizophrenia Patients (n=186) Healthy Volunteers (n=176)
Hippocampus
 Left 4106 (516) 4279 (483)
 Right 4201 (531) 4348 (462)
Amygdala
 Left 1629 (237) 1655 (213)
 Right 1686 (233) 1728 (241)
Caudate
 Left 3702 (540) 3721 (502)
 Right 3729 (539) 3756 (545)
Putamen
 Left 5935 (832) 5837 (669)
 Right 5596 (810) 5435 (633)
Pallidum
 Left 1883 (250) 1813 (229)
 Right 1720 (237) 1625 (206)
Thalamus
 Left 7154 (905) 7272 (876)
 Right 7334 (906) 7457 (831)
Lateral Ventricle
 Left 8705 (5539) 7605 (4091)
 Right 7920 (4784) 6958 (4034)
Intracranial Volume 1539 (177) 1562 (156)
The absolute volumes are presented as mean mm3 (SD) except for the Intracranial volume which is presented as mean cc3 (SD).
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